[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Kanthan R, Senger JL, Diudea D: Pulmonary lymphangitic carcinomatosis from squamous cell carcinoma of the cervix. World J Surg Oncol; 2010;8:107
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphangitic carcinomatosis from squamous cell carcinoma of the cervix.
  • INTRODUCTION: Pulmonary metastasis presenting as lymphangitic carcinomatosis arising from squamous cell carcinoma (SCC) of the cervix is a rare event.
  • Poorly represented in the literature, this event is associated with a) difficulty in accurate diagnosis, b) grave prognosis, and the c) lack of recognized predisposing risk factors.
  • A chest x-ray and computed tomography (CT) scan revealed multiple bilateral patchy areas with subsegmental atelectasis in both lungs which was investigated with a bronchoscopy, left thoracoscopy, and a left lung biopsy.
  • This lymphangitic carcinomatosis was confirmed to be metastatic from SCC of the cervix that had been diagnosed and treated two years ago.
  • She was treated with systemic Carbo/Taxol chemotherapy and corticosteroids as a palliative measure.
  • CONCLUSION: Pulmonary lymphangitic carcinomatosis is a rare manifestation of metastatic SCC of the cervix.
  • As clinical presentations including radiographic imaging mimics other pulmonary entities, accurate diagnosis remains a challenge.
  • Increased clinical awareness of such patterns of metastases in cervical cancer supported by accurate pathological diagnosis is imperative to guide appropriate therapy in these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lung Neoplasms / secondary. Lymphangitis / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome


2. Kikuchi N, Shiozawa T, Ishii Y, Satoh H, Noguchi M, Ohtsuka M: A patient with pulmonary lymphangitic carcinomatosis successfully treated with TS-1 and cisplatin. Intern Med; 2007;46(8):491-4
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with pulmonary lymphangitic carcinomatosis successfully treated with TS-1 and cisplatin.
  • He received chemotherapy containing TS-1 and cisplatin.
  • Pulmonary lymphangitic carcinomatosis disappeared and the patient achieved a good partial response.
  • He survived for 14 months after the chemotherapy.
  • We believe the combination of TS-1 and cisplatin is one of the attractive options for patients with cancer of unknown primary site.
  • [MeSH-major] Carcinoma / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Silicates / administration & dosage. Titanium / administration & dosage
  • [MeSH-minor] Adult. Drug Therapy, Combination. Humans. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17443041.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. de Albuquerque Filho AP: Exogenous lipoid pneumonia: importance of clinical history to the diagnosis. J Bras Pneumol; 2006 Nov-Dec;32(6):596-8
Genetic Alliance. consumer health - Exogenous Lipoid Pneumonia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exogenous lipoid pneumonia: importance of clinical history to the diagnosis.
  • Lipoid pneumonia is a rare disease resulting from the micro-aspiration of lipid formulations.
  • Making a diagnosis of lipoid pneumonia requires a high degree of clinical suspicion.
  • Herein, we report the case of a female patient with a history of breast cancer, presenting progressive dyspnea and cough, together with radiological findings of bilateral pulmonary infiltrate.
  • The working diagnosis of lymphangitic carcinomatosis, for which chemotherapy would be indicated, was called into question based on the high-resolution computed tomography findings and on the fact that the patient had a history of chronic ingestion of laxatives containing mineral oil.
  • A lung biopsy confirmed a diagnosis of lipoid pneumonia, which should always be considered in patients with diffuse lung disease having been exposed to potential causative agents.
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Medical History Taking / standards. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17435913.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cathartics; 8020-83-5 / Mineral Oil
  •  go-up   go-down


Advertisement
4. Palaia I, Angioli R, Cutillo G, Manci N, Panici PB: Skin relapse from cervical cancer. Gynecol Oncol; 2002 Oct;87(1):155-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin relapse from cervical cancer.
  • BACKGROUND: Cutaneous lymphangitis carcinomatosis from cervical carcinoma is a very rare form of tumor metastatization; only anecdotal cases are reported in the literature.
  • CASE: A case of cutaneous lymphangitis carcinomatosis mimicking contact dermatitis was diagnosed at our institution in a patient affected by cervical carcinoma stage IIB.
  • Palliative chemotherapy with paclitaxel was started and the patient experienced complete clinical response.
  • CONCLUSION: In a woman with a history of cervical cancer, a diffuse pruritic skin eruption should alert the clinician to the possibility of cutaneous carcinomatous lymphangitis.
  • If a lymphangitis carcinomatosis is diagnosed, systemic intravenous chemotherapy should be considered.
  • [MeSH-minor] Female. Humans. Lymphangitis / pathology. Middle Aged. Paclitaxel / therapeutic use


5. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult T-cell leukemia/lymphoma with primary lung cancer].
  • Cranial MRI showed an enlarged mass 5cm in diameter with intracranial invasion and metastatic brain tumors.
  • The mass was pathologically diagnosed as adult T-cell leukemia/lymphoma (ATLL) because of a high HTLV-1 antibody titer, and radiation therapy was started.
  • The primary lesion was the lungs, with bilateral pleural effusion and lymphangitis carcinomatosis.
  • We diagnosed stage IV primary lung cancer and started chemotherapy.
  • However, he developed dyspnea due to pleural effusion and his performance status gradually decreased to 3.
  • Autopsy showed ATLL and extensive lung cancer with multiple metastases.
  • CONCLUSION: We encountered a rare case of ATLL and primary lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Yamagishi Y, Akiba Y, Izumiya M, Higuchi H, Iizuka H, Takaishi H, Nagata H, Hibi T: [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1167-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
  • Chemotherapies for recurrent gastric cancer have not yet been established.
  • Here we report a case of type 4 gastric cancer associated with lymphangitis carcinomatosis which became refractory to the previous chemotherapies.
  • She had been diagnosed with gastric cancer after a Krukenberg tumor operation.
  • Disease activity has been well controlled until this time.
  • Since recurrence of left pleural effusion and lymphangitis carcinomatosis was recognized, we changed the chemotherapy TS-1 plus CPT-11.
  • Pleural effusion decreased and lymphangitis carcinomatosis improved.
  • The serum CA 19-9 level rose transiently after CPT-11 administration, and tended to fall at the second week of chemotherapy.
  • TS-1 plus CPT-11 combination chemotherapy would be effective for lymphangitis carcinomatosis and also useful as third-line chemotherapy for recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Krukenberg Tumor / surgery. Lymphangitis / complications. Ovarian Neoplasms / surgery. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Combinations. Female. Humans. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121922.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Yamada N, Okuse C, Nomoto M, Orita M, Katakura Y, Ishii T, Shinmyo T, Osada H, Maeda I, Yotsuyanagi H, Suzuki M, Itoh F: Obstructive jaundice caused by secondary pancreatic tumor from malignant solitary fibrous tumor of pleura: a case report. World J Gastroenterol; 2006 Aug 14;12(30):4922-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 77-year-old man on systemic chemotherapy against postoperative bilateral multiple lung metastases of malignant solitary fibrous tumor of the pleura suffered from pruritus and jaundice.
  • Abdominal computed tomography showed a tumor with peripheral enhancement in the pancreatic head, accompanied with the dilatation of intra- and extra-hepatic bile ducts.
  • The pancreatic head tumor was presumably diagnosed as the metastasis of malignant solitary fibrous tumor of the pleura, because the findings on the pancreatic head tumor on abdominal CT were similar to those on the primary lung lesion of malignant solitary fibrous tumor of the pleura.
  • The patient died of lymphangitis carcinomatosa of the lungs.
  • [MeSH-major] Jaundice, Obstructive / etiology. Neoplasms, Fibrous Tissue / pathology. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / secondary. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2001 Sep;51(9):686-90 [11696171.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):538-43 [15086281.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):25-30 [10458214.001]
  • [Cites] Clin Radiol. 1982 May 3;33(3):297-9 [7075134.001]
  • [Cites] Ann Intern Med. 1985 Apr;102(4):487-90 [2983594.001]
  • [Cites] Surg Gynecol Obstet. 1989 Apr;168(4):345-7 [2928909.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • (PMID = 16937484.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC4087636
  •  go-up   go-down


8. Naito T, Hasegawa H, Asada K, Suda T, Chida K: Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib. Clin Oncol (R Coll Radiol); 2006 Sep;18(7):573-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Carcinoma. Lung Neoplasms / drug therapy. Lymphangitis. Quinazolines / pharmacology
  • [MeSH-minor] Female. Forecasting. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969991.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


9. Storck K, Crispens M, Brader K: Squamous cell carcinoma of the cervix presenting as lymphangitic carcinomatosis: a case report and review of the literature. Gynecol Oncol; 2004 Sep;94(3):825-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the cervix presenting as lymphangitic carcinomatosis: a case report and review of the literature.
  • BACKGROUND: Lymphangitic carcinomatosis (LC) secondary to carcinoma of the cervix is rare.
  • The presenting symptoms are misleading and nonspecific, which often leads to delayed diagnosis.
  • CONCLUSIONS: Pulmonary LC is a rare but important manifestation of metastatic cervical cancer.
  • Patients present with severe respiratory compromise, which mimics other, more common disease states.
  • Diagnosis can be achieved by transbronchial biopsy.
  • Optimal treatment of the patient with LC is not well defined, but a trial of chemotherapy and/or intravenous steroids may be warranted.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Lymphangitis / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


10. Baiocchi G, Neto RC, Fukazawa EM, Faloppa CC, Avertano-Rocha AB, Begnami MD: Recurrent cervical cancer presented with lymphangitic carcinomatosis. J Obstet Gynaecol Res; 2010 Oct;36(5):1130-2
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent cervical cancer presented with lymphangitic carcinomatosis.
  • Lymphangitic carcinomatosis of the lungs secondary to cervical cancer is a rare condition.
  • Diagnosis is often delayed due to the common symptoms of nonproductive cough and dyspnea.
  • Only three reported patients received palliative chemotherapy.
  • We describe a case that has successfully received platinum-based chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lung Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21058448.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


11. Sogabe S, Yuki S, Takagi T, Miyazaki T, Takano H, Kawamoto Y, Nakatsumi H, Sasaki T, Iwanaga I, Uehata Y, Asaka M, Komatsu Y: [A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs]. Gan To Kagaku Ryoho; 2010 Mar;37(3):535-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
  • At the time of admission, he had dyspnea, and computed tomography (CT) showed typical signs of lymphangitis carcinomatosa of the lung.
  • After start of the therapy, CT revealed an improvement in lymphangitis carcinomatosa.
  • 8 months later, the tumor assessment became progressive disease.
  • FOLFIRI was started as the second-line chemotherapy, but the patient did not respond.
  • Then, dyspnea emerged again, and CT indicated the lymphangitis carcinomatosa had become worse.
  • So as the third-line chemotherapy, combination of irinotecan and cetuximab was started.
  • Dyspnea immediately disappeared, and CT showed an improvement of lymphangitis carcinomatosa.
  • In the previous literature, malignant tumor cases which accompany lymphangitis carcinomatosa might always have a poor course.
  • Our case dramatically responded to the chemotherapy including molecular targeting drug and showed a long survival.
  • So we conclude that aggressive chemotherapy including a molecular targeting drug may be recommended in a case of colorectal cancer which accompanies lymphangitis carcinomatosa of the lung.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphangitis / etiology. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Drug Delivery Systems. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Organoplatinum Compounds / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332699.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol
  •  go-up   go-down


12. Yamagishi Y, Okada Y, Ishikawa M, Mizuno A, Katano K, Fujita M: [A case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa successfully treated with mFOLFOX6 chemotherapy as salvage]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1959-63
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa successfully treated with mFOLFOX6 chemotherapy as salvage].
  • We report a case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa that responded to mFOLFOX6 chemotherapy and enabled survival for 19 months.
  • Interstitial pneumonia was suspected, and we started treatment with steroid medication, but this had no effect.
  • A colonoscopy and barium enema revealed diffusely infiltrating rectal cancer.
  • Abdominal CT and PET showed lymphangitis carcinomatosa of the lung, paraaortic lymph node swelling, and left hydronephrosis due to rectal cancer.
  • The patient was diagnosed with stage IV rectal cancer.
  • Because of subileus, we performed a decompression loop colostomy in the transverse colon, and started treatment with mFOLFOX6 chemotherapy as salvage in spite of the patient's poor respiratory condition.
  • Though the patient's tumor markers were very high (CEA 107 ng/mL, CA19-9 7,940 U/mL) prior to chemotherapy, they decreased dramatically (CEA 49.7 ng/mL, CA19-9 772 U/mL), and subjective symptoms (dry cough and dyspnea) also improved after 2 courses.
  • After 3 courses of treatment the patient was discharged.
  • This condition was maintained for 19 months by ambulant chemotherapy without sacrificing high quality of life.
  • Thus, mFOLFOX6 chemotherapy could be an effective salvage regimen in cases of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Diseases, Interstitial / drug therapy. Lung Diseases, Interstitial / etiology. Lymphangitis / drug therapy. Lymphangitis / etiology. Rectal Neoplasms / complications. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / blood. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Organoplatinum Compounds / therapeutic use. Salvage Therapy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011352.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


13. Watanabe T, Kawabata H, Takase I, Murata A, Nakajima H: [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1]. Gan To Kagaku Ryoho; 2003 Jun;30(6):849-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with lymphangitis carcinomatosa of the lung, successfully treated with paclitaxel and TS-1].
  • A 65-year-old man, who had been admitted to another hospital with complaints of severe cough and dyspnea, was transferred to our hospital for the further examination and therapy.
  • The patient was diagnosed with advanced gastric cancer (type-3) with lymphangitis carcinomatosa of the lung.
  • He was treated with combination therapy of 5-FU and cisplatin, and showed a complete response.
  • However, because resistance was seen in the lymphangitis of the lung and the gastric lesion; and a liver metastasis was also seen, we attempted combination therapy with paclitaxel and TS-1.
  • Sixty mg/m2/day of paclitaxel was administered intravenously on day 1 and 8, and TS-1 of 60-80 mg/m2/day was administered orally for 2 weeks followed by one drug-free week.
  • After 2 courses of the combination therapy, the patient achieved a remarkable response in the lymphangitis carcinomatosa of the lung, but a slight response in the liver metastasis and gastric lesion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / complications. Lymphangitis / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Combinations. Drug Resistance, Neoplasm. Fluorouracil / administration & dosage. Humans. Liver Neoplasms / secondary. Male. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852355.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


14. Mizuiri H, Yoshida K, Shimizu K, Tanabe K, Taomoto J, Suzuki T, Wada Y, Hihara J: [Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2043-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy].
  • The patient was a 58-year-old man who suffered from non-resectable gastric cancer, staged intraoperatively for peritoneal dissemination and paraaorta lymph node metastasis at another hospital in December 2002.
  • He was diagnosed with gastric cancer duodenum invasion, obstructive jaundice and lymphangitis carcinomatosa, and began weekly TXL as second-line chemotherapy on March 26.
  • One week after the first infusion therapy, the jaundice and dyspnea were greatly improved.
  • CT scan showed the lymphangitis carcinomatosa had disappeared and paraaorta lymph node metastasis was reduced to 60% after one cycle of the treatment.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Lymph Nodes / pathology. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Alopecia / chemically induced. Drug Administration Schedule. Duodenal Neoplasms / pathology. Humans. Jaundice, Obstructive / pathology. Leukopenia / chemically induced. Lymphangitis / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570937.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Takeuchi I, Ishida H, Suzuki T, Nakada H, Yamada H, Idezuki Y, Hohya I: [A case of diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa effectively treated with sequential MTX.5-FU and 5'-DFUR]. Gan To Kagaku Ryoho; 2000 Feb;27(2):289-93
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa effectively treated with sequential MTX.5-FU and 5'-DFUR].
  • A 37-year-old man was diagnosed as having a diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa.
  • Sequential methotrexate (MTX).5-fluorouracil (5-FU) therapy with oral administration of doxifluoridine (5'-DFUR) was started.
  • After 9 cycles of the MTX.5-FU therapy (total dose: MTX = 900 mg/body, 5-FU = 7,500 mg/body), radiographic examinations showed a partial response in the primary and pulmonary lesion, and paraaortic lymph nodes.
  • Histological evaluation of the resected specimen by Hartmann's operation showed a grade 2 effect in the primary lesion and metastatic lymph nodes.
  • This chemotherapy was repeated postoperatively.
  • The patient died of pulmonary disease, deteriorating rapidly 60 days postoperatively.
  • Diffusely infiltrating carcinoma of the large-bowel is generally far advanced at the time of diagnosis.
  • The results suggest that sequential MTX.5-FU therapy and oral administration of 5'-DFUR are worth performing in clinical trials for patients with diffusely infiltrating carcinoma of the large-bowel.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphangitis / complications. Sigmoid Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage

  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700903.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Miura T, Yamada S, Maruyama G, Nakamura J, Miura T, Yanagi M, Takahashi T: [A pregnant woman with inoperable advanced gastric cancer who received systemic anti-cancer chemotherapy after the non-full term fetus delivery by cesarean section]. Nihon Shokakibyo Gakkai Zasshi; 2009 Oct;106(10):1500-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pregnant woman with inoperable advanced gastric cancer who received systemic anti-cancer chemotherapy after the non-full term fetus delivery by cesarean section].
  • Examinations revealed an advanced gastric cancer with multiple liver, bone, lymph node metastasis and mesenteric dissemination, thus she was transferred to our division at 27 weeks and 1 day-gestation.
  • With her consent we decided to maintain her pregnancy until 28 weeks when the delivered fetus could be kept alive an incubator, avoiding the adverse effect on the fetus by anti-cancer chemotherapy to mother.
  • The mother complained of respiratory distress and suffered from lymphangitis carcinomatosa on the 3 postoperative day.
  • We began combination chemotherapy with S-1 and paclitaxel (S-1 100 mg/day, 3 weeks on, 2 weeks off and paclitaxel 70 mg/day on 1, 8 and 15) was started on the 4th postoperative day.
  • Although temporary regression of lymphangitis carcinomatosa was seen with a relief of symptoms, her condition deteriorated on the 24th days.
  • The second course chemotherapy was started on the 28th days without any relief of symptoms.
  • The association of pregnancy and gastric cancer is rare but such cases are often in an advanced clinical stage, with bad prognosis.
  • It is necessary to determine the treatment strategy on the basis of comprehensive consideration of the status of both the mother and fetus.
  • Upper gastrointestinal endoscopy when gastric cancer is suspected is recommended in any pregnant woman with long-term morning sickness.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cesarean Section. Pregnancy Complications, Neoplastic / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Infant, Newborn. Pregnancy

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834298.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


17. Takahashi K, Miyagawa K, Mitachi Y, Masuda T, Oogoshi T: [A case of gastric cancer with metastasis to cervical lymph nodes and pulmonary lymphangitis carcinomatosa responding to neoadjuvant chemotherapy with TS-1 and CDDP]. Gan To Kagaku Ryoho; 2003 May;30(5):685-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with metastasis to cervical lymph nodes and pulmonary lymphangitis carcinomatosa responding to neoadjuvant chemotherapy with TS-1 and CDDP].
  • The patient was a 61-year-old man who had gastric cancer with metastasis to cervical lymph nodes and pulmonary lymphangitis carcinomatosa.
  • He received daily oral administration of 120 mg of TS-1 (day 1-21) and systemic administration of 100 mg of CDDP (day 8) as one treatment course.
  • As the metastatic lesions had disappeared after chemotherapy, he underwent total gastrectomy.
  • Histopathological examination of resected regional lymph nodes revealed marked fibrosis and a small amount of scattered cancer cells.
  • Although much peritoneal dissemination was observed macroscopically, histopathological examination of these tumors revealed only fibrosis with no cancer cells.
  • These findings supported the effect of this neoadjuvant chemotherapy.
  • He died of recurrence of the carcinoma 203 days after surgery, without any sign of recurrence of metastasis to cervical lymph nodes or pulmonary lymphangitis carcinomatosa.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Lung Neoplasms / secondary. Lymphangitis / complications. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Combinations. Gastrectomy. Humans. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795102.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Gika M, Eguchi K, Inoue Y, Izawa N, Takeuchi K, Nakayama M: [Successful management of a patient with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for non-small cell lung cancer (NSCLC) in whom optimal dosages of transdermal fentanyl were determined by titration with fentanyl injection, and oxycodone hydrochloride]. Gan To Kagaku Ryoho; 2010 Mar;37(3):547-50
Hazardous Substances Data Bank. OXYCODONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful management of a patient with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for non-small cell lung cancer (NSCLC) in whom optimal dosages of transdermal fentanyl were determined by titration with fentanyl injection, and oxycodone hydrochloride].
  • With recent progress in disease-modifying treatments for cancer, patients who have recurrences during a period of several years before entering the terminal stage are encountered frequently.
  • Despite improved life expectancy with cancer therapy, for patients this means prolongation of the period in which various symptoms such as cancer pain and adverse reactions are undergone.
  • In these conditions, although the recognition is not yet sufficient, the importance of palliative care along with disease-modifying treatment is recognized in Japan.
  • We treated a 50s female with pain and dyspnea from bone metastasis and lymphangitis carcinomatosa after surgery for NSCLC in whom the optimal dosages of transdermal fentanyl (Durotep Patch) were determined by titration with fentanyl injection, and oxycodone hydrochloride (OxyContin) in a short period.
  • [MeSH-major] Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Dyspnea / drug therapy. Fentanyl / administration & dosage. Lung Neoplasms / surgery. Lymphangitis / etiology. Lymphangitis / physiopathology. Oxycodone / administration & dosage. Pain / drug therapy


19. Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K: A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Gastric Cancer; 2006;9(3):185-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
  • BACKGROUND: Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions.
  • We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric cancer.
  • The median survival time was 211 days.
  • CONCLUSION: MFP therapy is useful for the management of diffuse-type inoperable and recurrent gastric cancer, even in patients with conditions such as pleural effusion, ascites, or lymphangitis carcinomatosa who have a poor prognosis or cannot eat solid food.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1321-4 [4076293.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1215-7 [3756943.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2091-3 [7857709.001]
  • [Cites] Eur J Cancer. 1990 Jan;26(1):63-5 [2138482.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jul;19(7):946-53 [1626950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] Cancer Treat Rep. 1984 Dec;68(12):1497-8 [6542449.001]
  • [Cites] Eur J Surg Oncol. 1987 Jun;13(3):203-6 [3036603.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):751-4 [1801881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Am J Clin Oncol. 1983 Feb;6(1):35-8 [6682284.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Aug;14(8):2482-90 [3619460.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):18-22 [6317158.001]
  • [Cites] Cancer Treat Rep. 1985 Apr;69(4):449-50 [4039628.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):717-20 [6683644.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):167-72 [8500219.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):215-21 [1341254.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):67-8 [2720894.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Treat Rep. 1982 Sep;66(9):1713-7 [7116348.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3091-5 [4760525.001]
  • [Cites] Lancet. 1986 Feb 1;1(8475):256-8 [2868265.001]
  • (PMID = 16952036.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Etienne-Mastroïanni B, Freyer G, Cordier JF: [Secondary lung cancers]. Rev Prat; 2003 Apr 1;53(7):756-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary lung cancers].
  • Lung is the most common site of metastatic involvement for many malignant tumors.
  • The most frequent abnormalities are solitary or multiple pulmonary nodules (large "cannonball" nodules or diffuse miliary pattern), and lymphangitic carcinomatosis.
  • Most patients receive palliative treatment with chemotherapy, or hormone therapy (for metastases of breast cancer, thyroid, endometrial carcinoma or prostatic cancer).
  • [MeSH-major] Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12879800.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


21. Rubens RD: 7. Management of advanced breast cancer. Int J Clin Pract; 2001 Dec;55(10):676-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7. Management of advanced breast cancer.
  • Approximately half the patients with breast cancer relapse with locally recurrent or metastatic disease.
  • This disease is incurable but can often be controlled, sometimes for many years.
  • Selection of systemic treatment is based on three key factors: the extent, pattern and aggressiveness of the disease; hormone sensitivity; and menstrual status.
  • Chemotherapy is used for rapidly progressing visceral disease such as lymphangitis carcinomatosa or hepatic metastases with deranged liver biochemistry where death ensues rapidly unless disease progression can be reversed.
  • With less aggressive disease, treatment is planned around the oestrogen and progesterone status of the tumour.
  • Those with low tumour receptor levels are unlikely to respond to endocrine treatment and chemotherapy should be considered.
  • For patients with steroid receptor-positive tumours, endocrine treatment is used before chemotherapy is needed and consideration of menstrual status can assist in the selection of the precise approach.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Brain Neoplasms / secondary. Female. Humans. Liver Neoplasms / secondary. Neoplasm Metastasis. Pleural Effusion / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11777292.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 7
  •  go-up   go-down


22. Tucakovic M, Bascom R, Bascom PB: Pulmonary medicine and palliative care. Best Pract Res Clin Obstet Gynaecol; 2001 Apr;15(2):291-304
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parenchymal metastases are typically multifocal and respond to chemotherapy, with a limited role for pulmonary metastatectomy.
  • Pulmonary tumour embolism is frequently associated with lymphangitic carcinomatosis, and is most common in choriocarcinoma.
  • Thromboembolic disease, associated with the hypercoagulable state of cancer, is treated with anticoagulation.
  • Opiates are effective at relieving dyspnoea associated with effusions, metatases, and lymphangitic tumour spread.
  • Non-pharmacological therapies include energy conservation, home redesign, and dyspnoea relief strategies, including pursed lip breathing, relaxation, oxygen, circulation of air with a fan, and attention to spiritual suffering.
  • Identification and treatment of gastroesophageal reflux, sinusitis, and asthma can improve many patients' coughs.
  • [MeSH-major] Genital Neoplasms, Female / complications. Genital Neoplasms, Female / therapy. Lung Diseases / etiology. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Airway Obstruction / therapy. Cough / therapy. Dyspnea / therapy. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Meige Syndrome / surgery. Pleural Effusion, Malignant / therapy. Pulmonary Embolism / diagnosis. Pulmonary Embolism / drug therapy. Quality of Life. Vena Cava Filters

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11358403.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


23. Kokufu I, Tanei T, Taniguchi H, Kimura F, Fukuda K, Yamamoto M, Yano T, Yamada K: [A case of effective paclitaxel therapy for adriamycin resistant metastatic breast cancer with brain metastases]. Gan To Kagaku Ryoho; 2002 Apr;29(4):585-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective paclitaxel therapy for adriamycin resistant metastatic breast cancer with brain metastases].
  • Chest computed tomography revealed pulmonary metastases with lymphangitis carcinomatosa.
  • The patient was started on CA therapy (cyclophosphamide 900 mg, adriamycin 90 mg).
  • The primary breast cancer, liver metastases and axillary and cervical lymph node metastases were disappeared.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Drug Resistance, Neoplasm. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacology. Doxorubicin / pharmacology. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11977543.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, Stone P: A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med; 2001 Jan;15(1):3-8
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had advanced malignant disease and survived for a median of 40.5 days (range 1-398+ days) from the start of steroid treatment.
  • The most common specific indications for starting steroids were spinal cord compression, cerebral metastases, lymphangitis carcinomatosa and intestinal obstruction.
  • The most common side-effects that were most probably attributable to steroid therapy were oral candidosis and proximal myopathy.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antiemetics / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dexamethasone / therapeutic use. Glucocorticoids / therapeutic use. Palliative Care / methods
  • [MeSH-minor] Drug Administration Schedule. Drug Utilization. England. Follow-Up Studies. Humans. Practice Guidelines as Topic. Prospective Studies

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Palliat Med. 2001 Nov;15(6):521 [12403513.001]
  • (PMID = 11212465.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antiemetics; 0 / Antineoplastic Agents, Hormonal; 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


25. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, Hasegawa Y: Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer; 2006 Sep;53(3):387-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
  • We report the case of a woman with gefitinib-sensitive lung adenocarcinoma, who was successfully re-treated with gefitinib for carcinomatous meningitis as the disease recurrence.
  • The good response to gefitinib treatment was supported in part by the existence of epidermal growth factor receptor mutation in carcinoma cells in the specimen obtained from transbronchial lung biopsy, in which E709G in exon 18 and L858R in exon 21 were shown.
  • Although carcinomatous meningitis had been well controlled by the treatment with gefitinib, serum carcinoembryonic antigen (CEA) level increased with re-growth of primary tumor and development of lymphangitic carcinomatosis.
  • Immunohistochemical findings revealed de novo emergence of CEA-producing carcinoma cells in the biopsy specimen taken after recurrence of pulmonary lesion during re-treatment of gefitinib, but revealed little or no CEA expression in the specimen obtained at first presentation.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Biopsy. Carcinoembryonic Antigen / metabolism. Exons. Female. Humans. Magnetic Resonance Imaging / methods. Mutation. Receptor, Epidermal Growth Factor / genetics. Recurrence

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824645.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


26. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M: Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer; 2003 Apr;40(1):73-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
  • We describe the case of a 52-year-old Japanese woman with advanced adenocarcinoma of the lung, in whom once-daily treatment with 250 mg ZD1839 ('Iressa') demonstrated a marked antitumour effect.
  • She had initially achieved a partial response with cisplatin-based combination chemotherapy, but had subsequently progressed and had failed to respond to salvage chemotherapy.
  • On admission, the patient was confined to bed due to dyspnoea and had rapidly progressing hypoxia secondary to lymphangitis carcinomatosa and a massive right pleural effusion.
  • A month after starting ZD1839 treatment, the patient was discharged without the need for oxygen supplementation and had since returned to full-time work.
  • This is a demonstration of ZD1839 producing a dramatic clinical response when administered to a patient with poor performance status who had received extensive prior treatment with cytotoxic agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Enzyme Inhibitors / therapeutic use. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Quinazolines / therapeutic use. Taxoids
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Epidermal Growth Factor / antagonists & inhibitors. Female. Humans. Middle Aged. Neoplasm Staging. Protein-Tyrosine Kinases / antagonists & inhibitors. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2004 Mar;43(3):371-2 [15165100.001]
  • (PMID = 12660009.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 62229-50-9 / Epidermal Growth Factor; 7673326042 / irinotecan; EC 2.7.10.1 / Protein-Tyrosine Kinases; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


27. Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, Park CK: Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics; 2004 Jul-Aug;24(4):985-97; discussion 998
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
  • Radiation-induced lung disease (RILD) due to radiation therapy is common.
  • Radiologic manifestations are usually confined to the lung tissue within the radiation port and are dependent on the interval after completion of treatment.
  • However, the use of oblique beam angles and the development of newer irradiation techniques such as three-dimensional conformal radiation therapy can result in an unusual distribution of these findings.
  • Awareness of the atypical manifestations of RILD can be useful in preventing confusion with infection, recurrent malignancy, lymphangitic carcinomatosis, and radiation-induced tumors.
  • In addition, knowledge of radiologic findings that are outside the expected pattern for RILD can be useful in diagnosis of infection or recurrent malignancy.
  • A comprehensive understanding of the full spectrum of these manifestations is important to facilitate diagnosis and management in cancer patients treated with radiation therapy.
  • [MeSH-major] Lung / radiation effects. Radiation Injuries / radiography. Radiation Pneumonitis / radiography. Radiotherapy / adverse effects
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Breast Neoplasms / radiotherapy. Bronchiectasis / etiology. Bronchiectasis / radiography. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radiotherapy. Diagnosis, Differential. Disease Progression. Dose Fractionation. Esophageal Neoplasms / radiotherapy. Female. Hodgkin Disease / radiotherapy. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasms, Radiation-Induced / diagnosis. Radiation Tolerance / drug effects. Radiotherapy Dosage. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • (PMID = 15256622.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


28. Abe Y, Kurita S, Ohkubo Y, Usui H, Hashizume T, Nakamura M, Ueyama Y, Fujino T: A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res; 2002 Nov-Dec;22(6B):3485-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A transbronchial lung biopsy showed the features of adenocarcinoma.
  • Chest and abdominal computed tomography (CT) scan showed the features of lymphangitis carcinomatosa, and bilateral metastatic adrenal tumors.
  • After effective chemotherapy, he complained of arthralgia and a bone scintigram showed abnormal uptakes in his bilateral shoulder, knee and wrist.
  • He died of cachexia on May 2nd, 2001, more than 2 years after the diagnosis of pulmonary adenocarcinoma at stage IV.
  • [MeSH-major] Adenocarcinoma / complications. Endothelial Growth Factors / biosynthesis. Intercellular Signaling Peptides and Proteins / biosynthesis. Lung Neoplasms / complications. Lymphokines / biosynthesis. Osteoarthropathy, Secondary Hypertrophic / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12552943.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lymphokines; 0 / Mucins; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


29. Juan Vidal O, de Paz Arias L, Catalá Barceló J, García Escrig M: [Meningeal carcinomatosis as first manifestation of carcinoma of the bladder: report of 2 cases]. An Med Interna; 2000 Aug;17(8):425-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Meningeal carcinomatosis as first manifestation of carcinoma of the bladder: report of 2 cases].
  • [Transliterated title] Carcinomatosis meníngea como primera manifestación del carcinoma de vejiga: a propósito de dos casos.
  • Meningeal carcinomatosis may occur in 0.8-8% of patients with solid tumors.
  • The most common tumors associated with that condition are breast and small cell lung cancer.
  • Meningeal carcinomatosis from urothelial cancer is rare, and it appears described in advanced stages of disease, generally, after chemotherapy.
  • Two cases of meningeal carcinomatosis as the first manifestation of bladder cancer were reported.
  • In the second case, a 68-year-old man was admitted to our hospital with a history compatible with panhypopituitarism and pulmonary lymphangitic carcinomatosis from cancer of unknown primary site.
  • We emphasize in the polymorphic presentation of meningeal carcinomatosis and the necessity to consider the bladder as primary tumor localization.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218991.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


30. Iwamoto H, Sakai M, Yamane T, Shiota N, Shoda H, Bandobashi K, Kubota T, Yokoyama A: [A case of tumor microembolism diagnosed by perfusion scan and transbronchial lung biopsy]. Nihon Kokyuki Gakkai Zasshi; 2009 Aug;47(8):687-91
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of tumor microembolism diagnosed by perfusion scan and transbronchial lung biopsy].
  • A 70-year-old woman with breast cancer treated with hormonal therapy had progressive shortness of breath for one month.
  • Chest radiograph and computed tomography showed mild interstitial changes, but could not account for her respiratory failure.
  • Lymphangitic carcinomatosis, drug-induced pneumonitis, idiopathic interstitial pneumonitis, opportunistic infection, and pulmonary edema were considered in the differential diagnosis of the CT findings.
  • A perfusion scan revealed numerous small subsegmental perfusion defects in both lung fields.
  • Bronchoalveolar lavage fluid (BALF) contained some cancer cells, suggesting lymphangitic carcinomatosis.
  • Immunohistochemical findings of TBLB specimen were consistent with breast cancer cells.
  • A diagnosis of tumor microembolism caused by breast cancer metastasis was made.
  • Antemortem diagnosis of tumor microembolism is very difficult.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplastic Cells, Circulating

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764510.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement